Reference is made to the stock exchange release from Gentian 
Diagnostics AS ("Gentian" or the "Company") published 
yesterday regarding the contemplated private placement of up 
to NOK 100 million by issuance of up to 2,857,143 new shares 
at NOK 35 per share (the "Private Placement").

The Company announced today that it has placed 2,714,286 new 
shares (corresponding to NOK 95,000,010 in gross proceeds) 
in Tranche 1 of the Private Placement.

In connection with the Private Placement Trance 1, the 
following primary insiders have been allocated for shares in 
Gentian Diagnostics AS:


Chief Financial Officer Julie Alling Gryga, 

Details on the transaction:

Date of the transaction: 19.01.2017
Number of shares before trade: 0
Number of share acquired: 100
Number of shares after the trade: 100
Share price: NOK 35


Chairman of the Board John Afseth through his company Carpe 
Diem Afseth AS,

Details on the transaction:

Date of the transaction: 19.01.2017
Number of shares before trade: 92 320
Number of share acquired: 7 680
Number of shares after the trade: 100 000
Share price: NOK 35

Board member Ingrid Teigland Akay through her company Hadean 
Ventures AS,

Details on the transaction:

Date of the transaction: 19.01.2017
Number of shares before trade: 52 454
Number of share acquired: 6 000
Number of shares after the trade: 58 454
Share price: NOK 35

Board member Espen Tidemann JÃ¸rgensen through the company 
Holta Life Sciences AS,

Details on the transaction:

Date of the transaction: 19.01.2017
Number of shares before trade: 1 928 496
Number of share acquired: 100 000
Number of shares after the trade: 2 028 496
Share price: NOK 35

Allocation of the new shares is conditional on the Private 
Placement being completed. Completion of the Private 
Placement is subject to, inter alia, approval of the 
company's extraordinary general meeting in a meeting 
expected to be held 30 January 2017.

This notification is given according to Merkur Market's 
continuing obligations section 6.2.